QUOTE AND NEWS
StreetInsider.com  May 21  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/NxStage+%28NXTM%29%2C+DaVita+%28DVA%29+Enter+New+Supply+Agreements/8359827.html for the full story.
StreetInsider.com  May 2  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Nxstage+Medical%2C+Inc.+%28NXTM%29+Reports+In-Line+Q1+EPS%3B+Guides+Q2/8297544.html for the full story.
Benzinga  Apr 25  Comment 
NxStage Medical (NASDAQ: NXTM) announced today that Robert G. Funari has been appointed as the non-executive Chairman of the Board effective immediately. Mr. Funari is the former Chairman of Crescent Healthcare and has served on the NxStage Board...
StreetInsider.com  Mar 8  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Rockwell+%28RMTI%29%2C+NxStage+%28NXST%29+Enter+Manufacturing+Agreement/8168979.html for the full story.
StreetInsider.com  Feb 28  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/NxStage+Medical%2C+Inc.+%28NXTM%29+Tops+Q4+EPS+by+5c%3B+Issues+Light+Outlook/8142077.html for the full story.
Benzinga  Nov 9  Comment 
In a report published Friday, Jefferies & Company reiterated its Buy rating on NxStage Medical (NASDAQ: NXTM), but lowered its price target from $21.00 to $16.00. Jefferies noted, “NXTM posted a decent 3Q. Overall HHD grew 17% but US HHD...
Benzinga  Nov 9  Comment 
NxStage® Medical (NASDAQ: NXTM), a leading manufacturer of innovative dialysis products, today announced the appointment of Jean Mixer to its Board of Directors. Ms. Mixer is the Chief Executive Officer of mixerconsulting which focuses on...
StreetInsider.com  Nov 8  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Nxstage+Medical%2C+Inc.+%28NXTM%29+Tops+Q3+EPS+by+2c%3B+Lowers+FY12+Outlook/7856164.html for the full story.
StreetInsider.com  Oct 10  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Upgrades/Upgrade+Could+Mean+NxStage+%28NXTM%29+Decline+Finally+Over/7783021.html for the full story.
Benzinga  Sep 28  Comment 
Feltl and Company reiterated its Hold rating and $15 price target on NxStage Medical (NASDAQ: NXTM) as it tweaked the revenue forecast for 2012 to reflect shift in shipment from the third quarter to the fourth. Feltl and Company noted, "We are...





You may also be interested in articles related to NxStage Medical (NXTM):
 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki